✦ LIBER ✦

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

✍ Scribed by W. K. Hofmann; G. Heil; C. Zander; S. Wiebe; O. G. Ottmann; L. Bergmann; K. Hoeffken; J. T. Fischer; A. Knuth; K. Kolbe; H. J. Schmoll; W. Langer; M. Westerhausen; C. B. Koelbel; D. Hoelzer; A. Ganser

Publisher: Springer
Year: 2004
Tongue: English
Weight: 109 KB
Volume: 83
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-004-0889-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Idarubicin, cytarabine, and topotecan in

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome

✍ Seung Tae Lee; Joon Ho Jang; Hyung Chan Suh; Jee Sook Hahn; Yun Woong Ko; Yoo Ho 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Intensive chemotherapy with idarubicin,

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)

✍ A. Ganser; G. Heil; G. Seipelt; W. Hofmann; J. T. Fischer; W. Langer; W. Brockha 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 104 KB

A phase I/II study of oral etoposide and

A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy

✍ Michael Fiegl; Thomas Büchner; Wolfgang Hiddemann; Jan Braess 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 84 KB

A phase 1-2 study of a farnesyltransfera

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2

Aggressive chemotherapy combined with G-

Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia — initial results

✍ A. Ganser; G. Heil; K. Kolbe; G. Maschmeyer; J. T. Fischer; L. Bergmann; P. S. M 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 240 KB

Gemtuzumab, fludarabine, cytarabine, and

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

✍ Apostolia Tsimberidou; Elihu Estey; Jorge Cortes; Deborah Thomas; Stefan Faderl; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Background: Gemtuzumab is used to treat patients with previously untreated or recurrent acute myelogenous leukemia (aml). the fludarabine and cytarabine (ara-c) regimen is active in these patients. resistance to gemtuzumab is associated with blast multidrug resistance (mdr). the objectives of th